OBJECTIVETo investigate clinical outcomes of tendon allograft reconstruction with arthroscopy minimally invasive technique at stage I for the treatment of knee dislocation with multiple ligaments injury.

METHODSForty-eight patients with knee dislocation were reconstructed anterior and posterior ligament under arthroscopy at stage I from January 2008 to January 2012, and repaired ligaments injury of knee joint by minimally invasive technique. There were 38 males and 10 females aged from 20 to 59 years old with an average of 35.6 years old; 22 cases on the left side and 26 cases on the right side; the time from injury to operation ranged from 2 d to 2 weeks. Two cases combined with anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), medial collateral ligament (MCL) and posterolateral complex injuries, 36 cases combined with ACL, PCL, and MCL injuries, 10 cases combined with ACL, PCL and PLC injuries; 4 cases combined with peroneal nerve injury. Lysholm scoring were used to compared the cases before operation and final following-up to evaluate knee function.

RESULTSAll patients were followed up from 12 to 30 months with an average of (18.2 ± 6.3) months. Activity and stability of joint were obviously improved. Lysholm score were improved from 40.3 ± 4.1 before operation to 87.0 ± 6.4 at final following-up.

CONCLUSIONReconstruction with arthroscopy minimally invasive technique at stage I for the treatment of knee dislocation with multiple ligaments injury could recover stability of joint better,reserve joint function. Preoperative training and postoperative individualized rehabilitation treatment is the key point of recover knee joint function.

Adult ; Anterior Cruciate Ligament Injuries ; Arthroscopy ; Female ; Humans ; Knee Dislocation ; rehabilitation ; surgery ; Male ; Middle Aged ; Multiple Trauma ; surgery ; Posterior Cruciate Ligament ; injuries ; Reconstructive Surgical Procedures ; methods

OBJECTIVETo investigate the sociopsychological basis of hypertensive disorder in pregnancy (HDP) and explore a new pathway for etiological study of HDP.

METHODSA prospective investigation was conducted in 1154 women in second trimester pregnancy and 9 factors were surveyed using Olson marital quality questionnaire (ENRIC). The discrepancy between the norms and factor scores of ENRIC was analyzed, and the scores of ENRIC were compared between normal gravidas and patients with HDP. The correlation between ENRIC scores and the severity of the condition was also evaluated.

RESULTSThe score of the 1124 gravidas for marital satisfaction was significantly higher than the norm (P<0.05), but the scores for relationship with relatives and sexual life were significantly lower (P<0.05). The other 6 factors had similar scores with the norms (P>0.05). Patients with HDP had significantly lower scores for 7 factors than the normal gravidas (P<0.05), but had comparable scores for financial arrangement and sexual life (P>0.05). The severity of HDP was not found to associate with variation of the scores for the 9 factors (P>0.05).

CONCLUSIONSMarital quality is an important social and psychological basis of HDP, and this study provides some evidence for the social and psychological investigation of the etiology of HDP.

Adult ; Female ; Humans ; Hypertension ; epidemiology ; psychology ; Marriage ; psychology ; Pregnancy ; psychology ; Quality of Life ; psychology ; Surveys and Questionnaires ; Young Adult

OBJECTIVETo explore the risk factors of acute lymphoblastic leukemia (ALL) recurrence in adult patients and establish a prognosis index (PI) calculation model in order to improve the prevention strategy of ALL in adults.

METHODS104 adult ALL patients from Blood Diseases Hospital & Chinese Academy of Medical Sciences between August 2008 and November 2011 were enrolled. COX proportional hazards regression stratified by Dummy variable was used to set up the prediction model; Kaplan-Meier method and Log-rank test were used to estimate and compare the survival. After calculated individual PI value, patients' expected survival should be estimated by groups.

RESULTSThe overall median survival of adult ALL patients was 22.00 months (95% CI 17.00-27.00). COX regression analysis showed that chemotherapy group patients had a higher risk of recurrence than of ASCT group while setting treatment as the dummy variable (RR=2.052, 95%CI 0.877-4.799, P=0.007). Stratified Analysis showed that the risk factors of B-ALL recurrence in adult patients included HGB <100 g/L (RR=0.186, 95% CI 0.068-0.512, P=0.001), CNSL (RR=7.767,95% CI 2.951- 20.433, P=0.001), number of consolidation chemotherapy<3 (RR=0.445, 95% CI 0.211-0.940, P=0.034) and Ph chromosome positive (RR=2.771, 95% CI 1.353-5.674, P=0.005). Grouped by the PI value, the expected survival of each individual patient could be estimated as PI=0.58 base.

CONCLUSIONHGB, CNSL, number of consolidation chemotherapy and Ph chromosome were independent risk factors of B-ALL recurrence in adult patients. PI value could predict the survival of adult ALL patients and provide reference for individual therapy and prognostic evaluation.

Adolescent ; Adult ; Female ; Humans ; Male ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; epidemiology ; pathology ; Prognosis ; Recurrence ; Risk Assessment ; Risk Factors ; Young Adult

OBJECTIVE To characterize the molecular weight of Radix Isatidis protein(RIP)and optimize the extraction process of protein from Radix Isatidis.METHODS Response surface methodology(RSM)was applied to optimize the extrac-tion of protein from Radix Isatidis.Extraction time,liquid-to-solid ratio and pH value were set as the investigated factors with respect to the protein yield.In addition,Design Expert software was used for data analysis.The RIP was characterized for composition using sodium dodecyl sulfate-polyacrylamide gel electrophoresis(SDS-PAGE).Scanning electron microscopy(SEM)analysis was performed to observe microstructure of the Radix Isatidis powder before and after ultrasound-assisted ex-traction(UAE).RESULTS Based on the RSM analysis,optimum conditions were determined as follows:twice ultrasonic ex-traction in 50 mmol/L Tris-HCl buffer solution,pH at 7.8,liquid-to-solid ratio at 80:1 and extraction for 65 min each time.Under the optimized conditions,the experimental values were 0.705％,which is in close agreement with values predicted by the model.The characterization of the RIP demonstrated that it contained five major groups of protein bands,namely bands of 19.2 kDa,21.5 kDa,24.8 kDa,34～43 kDa and >170 kDa respectively.CONCLUSION RSM can be applied for the optimi-zation of extraction process of RIP,which is effective,stable and feasible.

OBJECTIVETo investigate the efficacy of imatinib in the treatment of chronic myeloid leukemia (CML) and analyse the treatment outcome and related factors.

METHODSNinety five CML patients were treated with imatinib in our hospital from May 2002 to May 2006. The outcomes and related factors were analysed.

RESULTS(1) One year after therapy, there were 95.5% of chronic phase (CP) patients achieved complete hematologic response (CHR). Fifty-two patients with complete cytogenetic dates were divided into primary-therapy group (n = 19) and secondary-therapy group (n = 33). The major cytogenetic responses (MCyR) at 6-, 12-, 18-, 24- and 30-months after therapy for the former group were 84.2%, 84.2%, 89.5%, 89.5% and 94.7%, and for the latter group were 36.4%, 39.4%, 39.4%, 39.4% and 39.4%, respectively (P < 0.01). The expected survival at 12-, 24-, 36- and 50-month after imatinib treatment for CP group was (98.1 +/-1.9)%, (87.8 +/- 7.1)%, (81.9 +/- 8.7)% and (81.9 +/- 8.7)%, respectively. (2) Twelve month after therapy, there are 70% of accelerated phase (AP) patients achieve CHR and 10% get MCyR. The expected survival at 12-, 24- and 36-month after imatinib treatment for AP group was (63.0 +/- 17.7)%, (15.8 +/- 14.3)% and (15.8 +/- 14.3)%, respectively. (3) Six month after therapy, 57.9% of blast crisis (BC) patients achieve CHR, with the expected survival at 12- and 24-month of (40.6 +/- 12.3)% and 0, respectively. (4) COX analysis CP group indicated that imatinib therapy administered for previously untreated was an independent favorable prognostic factor. Conclusion (1) Imatinib as a primary treatment for CP CML can significantly improve the survival time as compared with that AP or BC patients or with that used in previously treated patients. (2) Imatinib could induce hematologic, even cytogenetic response to a certain extent, in CP or BC patients and prolong the survival time.

Adolescent ; Adult ; Aged ; Antineoplastic Agents ; therapeutic use ; Benzamides ; Female ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; drug therapy ; Male ; Middle Aged ; Piperazines ; therapeutic use ; Pyrimidines ; therapeutic use ; Treatment Outcome ; Young Adult

OBJECTIVETo investigate the safety and efficacy of low-concentration inhaled nitric oxide (NO) in the treatment of hypoxic respiratory failure (HRF) among premature infants.

METHODSSixty premature infants (gestational age ≤ 34 weeks) with HRF were randomized into NO and control groups between 2012 and 2013, with 30 cases in each group. Both groups received nasal continuous positive airway pressure (nCPAP) or mechanical ventilation. NO inhalation was continued for at least 7 days or until weaning in the NO group. The general conditions, blood gas results, complications, and clinical outcomes of the two groups were analyzed.

RESULTSThe NO group showed significantly more improvement in blood gas results than the control group after 12 hours of treatment (P<0.05). After that, the change in oxygenation status over time showed no significant difference between the two groups (P>0.05). There were no significant differences in total time of assisted ventilation and duration of oxygen therapy between the two groups (P>0.05). The incidence of bronchopulmonary dysplasia (BPD), patent ductus arteriosus, necrotizing enterocolitis, retinopathy of prematurity, and pneumothorax in infants showed no significant differences between the NO and control groups (P>0.05), but the incidence of IVH and mortality were significantly lower in the NO group than in the control group (7% vs 17%, P<0.05; 3% vs 13%, P<0.05).

CONCLUSIONSNO inhalation may improve oxygenation status and reduce the mortality in premature infants with HRF, but it cannot reduce the incidence of BPD and the total time of mechanical ventilation or nCPAP and duration of oxygen therapy. NO therapy may have a brain-protective effect for premature infants with HRF and does not increase clinical complications.

Administration, Inhalation ; Blood Gas Analysis ; Bronchopulmonary Dysplasia ; epidemiology ; Humans ; Hypoxia ; complications ; Incidence ; Infant, Newborn ; Infant, Premature ; Nitric Oxide ; administration & dosage ; Respiratory Insufficiency ; blood ; complications ; drug therapy

Objective To investigate the relationship between the plasma macrophage migration inhibitory factor(MIF),activator protein-1 (AP-1) and MMP-9 concentrations and the severity of coronary artery lesions in coronary heart disease (CHD) patients.Methods Patients were divided into normal controls (n=35),stable angina pectoris (SAP,n=32) and acute coronary syndrome (ACS,n=75)according to the coronary angiography (CAG),clinical and laboratory examinations.The CAG severity and extent of coronary lesions were analyzed by means of Gensini coronary score system.Enzyme linked immunosorent assay was used to measure the plasma MIF,AP-1 and MMP-9 concentrations.Results Plasma MIF,AP-1 and MMP-9 concentrations were significant increased in CHD patients [MIF:(14.97±2.11)μg/L,AP-1:1.43±0.33,MMP-9:(1.48±0.14)μg/L] compared to those in control group [MIF:(9.07±1.28) μg/L,AP-1:0.71 ±0.13,MMP-9:(1.01±0.07) μg/L,all P＜0.05].The MIF,AP-1 and MMP-9 concentrations in ACS group [MIF:(16.66±2.56) μg/L,AP-1:1.56±0.22,MMP-9:(1.58±0.14) μg/L] were also significant higher than those in SAP group[MIF:(11.01±2.12) μg/L,AP-1:1.04±0.25,MMP-9:(1.25±0.07) μg/L,all P＜0.05] and there was significant positive correlation between MIF,AP-1 and MMP-9 concentrations and the Gemini score of coronary artery lesions (all P＜0.05).AP-1 was positively correlated with MMP-9 in CHD patients (P＜0.05).Conclusions Plasma MIF,AP-1 and MMP-9 concentrations were positively correlated to the severity of coronary lesions in CHD patients.Higher MIF,AP-1 and MMP-9 concentrations in ACS patients than in SAP patients might suggest higher plaque instability in ACS patients.

OBJECTIVETo assess efficacy and safety of alendronate sodium treatment in osteoporosis patients with hip fracture.

METHODSOne year randomized, double-blind clinical trial was carried out in 77 osteoporosis patients with hip fracture. The bone mineral density (BMD) in lumbar spine (L(2 - 4)), femoral neck (Neck), Wards triangle (Wards) and great trochanter (Troch) was measured by dual energy x-ray absorptiometer (DEXA).

RESULTSIn our study, alendronate sodium induced marked increases in BMD of the L(2 - 4) (7.0% +/- 13.0%), Neck (7.3% +/- 11.1%), Wards (4.6% +/- 5.9%), Troch (4.5% +/- 3.2%) (mean +/- s) versus decreases of 2.0% +/- 4.5%, -0.9% +/- 6.9%, 3.6% +/- 4.9% and 1.14% +/- 6.0% with placebo (P < 0.05). Blood Ca, P, ALP, BGP and Urine Pyd/C were no significant difference between before and after therapy. There were usually mild and transient side-effect, such as gastrointestinal symptoms.

CONCLUSIONAlendronate is an efficacy and safety drug in treatment of osteoporosis.

Absorptiometry, Photon ; Aged ; Alanine Transaminase ; blood ; Alendronate ; pharmacology ; therapeutic use ; Bone Density ; drug effects ; Calcium ; blood ; Case-Control Studies ; Double-Blind Method ; Female ; Hip Fractures ; complications ; Humans ; Male ; Middle Aged ; Osteoporosis ; blood ; complications ; drug therapy ; Treatment Outcome

Objective To analyze the results of detection on influenza A (H1N1) 2009 virus in Beijing from May 2009 to December 2009 and to understand the epidemiologic characteristics during the pandemic period. Methods The study was conducted from the May 1 to December 27,2009. A total of 101 852 throat swab samples were detected with the real-time RT-PCR assay by the Beijing Network Laboratory. Data was statistically analyzed. Results 9843 samples showed influenza A (H1N1) 2009 positive, with an overall positive rate as 9.66%. In terms of the positive rates, they were 2.85% from May to June, 3.32% from July to August and 8.35% from September to October. The peak month fell in November (29.67%) and December (24.33%). The positive rates among the following subpopulations were: 8.40% among the suspected cases, 4.75% among close contact cases, 11.46% among the influenza-like illness cases and 7.33% among the cluster cases with fever. Positive cases mainly fell in age groups 5-14 and 15-24. The ratio of male to female was 1.5:1.Conclusion During the pandemic period of influenza A (H1N1) 2009, positive cases gradually increased during May to November but slowly decreasing in December.

Background and Objective: Studies showed that cetuximab combined with chemotherapy was effective on advanced colorectal cancer (ACRC)in recent years,however,few reports based on large case cohort are available in China.This study was to analyze the efficacy of cetuximab combined with chemotherapy for 53 chinese patients with ACRC. Melhods:Clinical data of 53 patients with ACRC.treated with cetuximab combined with chemotherapy in Sun Yat-sen Cancer Center from March 2005 to April 2008,were analyzed for short-term efficacy and safety.The efficacy of the regimen used as first-line and non-first-line treatment was compared by Chi-square test;the effect of the regimen on prognosis was analyzed by multivariate Cox proportional hazards model.Results:Of the 53 patients with colorectal adenocarcinoma,40 were men and 13 were women, with a median age of 55 years. A total of 572 weeks(median,8 weeks) of cetuximab treatment were completed.The overall response rate(RR)of the regimen was 39.6%and the disease centrel rate 66.0%.The disease control rates were similar when the regimen was used as first-line and non-first-line treatment(80.3%MS.60.5%,P=0.177).For all 53 patients,clinical stage was an independent prognostic factor(P=0.002,OR>1).The most common Grade 3 to 4 adverse events included acne-like rash(7.5%),neutropenia (18.9%), and diarrhea (5.6%). No hypersensitive reaction or treatmentrelated death was observed. Only one patient discontinued treatment because of Grade 4 diarrhea and neutopenia. Conclusions: Cetuximab combined with chemotherapy can achieve relatively high disease control rate for ACRC patients.with less adverse events.Whether cetuximab has better effect in first-line treatment than in non-first-line treatment needs further study.